ArticleBMC pediatrics2025
Newborn RSV immunization rates and reasons compared to family COVID-19 and influenza immunization status.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a common viral infection with the potential for severe illness in infants, leading to thousands of pediatric hospitalizations annually. In late 2023, Beyfortus (nirsevimab), a long-acting monoclonal antibody, became available to provide passive RSV immunization for all newborns meeting eligibility criteria. This study aimed to explore parental decision-making regarding RSV immunization, particularly in comparison to family uptake of COVID-19 and influenza vaccines, within an urban, predominantly Medicaid population in North Philadelphia.
methodsThis qualitative study was conducted at Temple University Hospital and Temple Pediatric Care outpatient clinic. Semi-structured interviews were performed with 25 parents and primary caregivers of newborns who received RSV immunization during the 2023-2024 season. Participants were recruited from a retrospective list and interviewed by phone using a standardized questionnaire. Grounded Theory methodology was applied for data analysis using iterative coding to identify themes related to immunization perceptions and acceptance.
resultsParticipants expressed high levels of trust in healthcare providers and prioritized safety and efficacy when making immunization decisions. Parents accepted RSV immunization due to personal or family experiences with RSV, general desire to protect their newborns, or pediatrician recommendation. In contrast, COVID-19 and influenza vaccine decisions were less consistent. Concerns about side effects and perceived lack of effectiveness were common reasons for declining COVID-19 vaccines, despite similar motivations for protection. Social media and political beliefs had minimal reported influence. Parents reported a lack of consistent, reliable online sources for vaccine information, often relying on general internet searches. Many misunderstood immunization/vaccine efficacy, equating it with complete immunity rather than reduced disease severity.
conclusionsParental acceptance of RSV immunization was driven by protective instincts for newborns and familiarity with RSV as a disease. Hesitancy toward COVID-19 vaccination stemmed largely from concerns about effectiveness and confusion around immunization/vaccine purpose. Trust in medical professionals influenced decision-making, though participants lacked a consistent source of immunization information. Improved public education on immunization efficacy and centralized access to trustworthy information may enhance immunization uptake and address ongoing hesitancy across all pediatric immunizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.